BRNS Barinthus Biotherapeutics plc Forecast, Technical & Fundamental Analysis
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases... Show more
BRNS is expected to report earnings to rise 11.54% to -28 cents per share on November 05
Q3'26
Est.
$-0.29
Q2'26
Beat
by $0.02
Q1'26
Beat
by $0.18
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.04
The last earnings report on August 06 showed earnings per share of -25 cents, beating the estimate of -28 cents. With 9.17K shares outstanding, the current market capitalization sits at 25.44M.
A.I.dvisor indicates that over the last year, BRNS has been loosely correlated with NGNE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BRNS jumps, then NGNE could also see price increases.
BRNS saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for BRNS moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 43 similar instances where the indicator exited the overbought zone. In of the 43 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
BRNS moved below its 50-day moving average on August 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRNS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BRNS broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BRNS entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on BRNS as a result. In of 115 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BRNS just turned positive on August 07, 2026. Looking at past instances where BRNS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BRNS advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BRNS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.445) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.165) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
